Search Results
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanismsAdcendo will sponsor the Phase 1b clinical trial and MSD
More news about: Adcendo
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanismsAdcendo will sponsor the Phase 1b clinical trial and MSD will provide pembrolizumab
More news about: Adcendo
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
May 22, 2026, 08:30 ET Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence
Session: Gynecologic Cancer. Date/Time: Monday, June 1, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 275.Antibody drug conjugate (ADC) biomarker targets in endometrial cancer (EC): Molecular characterization and implications for therapeutic decision-making. (Abstract 5616) Session:
More news about: Caris Life Sciences
May 21, 2026, 23:30 ET Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
Nectin-4-targeting ADC independently developed by Mabwell based on its ADC development platform. Mabwell is currently conducting multiple clinical studies for several indications including urothelial carcinoma, cervical cancer, esophageal cancer and breast cancer. It is the world's first Nectin-4 ADC to enter
More news about: Mabwell
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-Biotech
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - NORTH
More news about: AbbVie
May 21, 2026, 17:34 ET Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago,
More news about: Formosa Pharmaceuticals Inc.,
May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into a new option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs. Whitehawk's ADC platform leverages CPT113 as the core linker-payload technology,
More news about: Whitehawk Therapeutics, Inc.
May 21, 2026, 17:00 ET New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
squamous cell carcinoma in ChinaDemonstrating breadth of ADC platform with updates from novel ADC programs:Results from the first Phase I study in China of BL-M14D1, a novel DLL3 directed ADC, in patients with locally advanced or metastatic small-cell lung cancer
More news about: SystImmune, Inc.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
advanced dedifferentiated liposarcoma.LY4052031 (investigational ADC targeting Nectin-4): In an oral presentation, initial results will be shared from the Phase 1 NEXUS-01 study evaluating LY4052031, an ADC targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma.Kelonia
More news about: Eli Lilly and Company
May 21, 2026, 17:00 ET Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
Servier.us.About Emi-LeEmi-Le is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary auristatin-F HPA payload with controlled bystander effect. This candidate
More news about: Servier Pharmaceuticals
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
May 20, 2026, 08:00 ET Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the TD Cowen 7th Annual
More news about: Whitehawk Therapeutics, Inc.
May 19, 2026, 20:00 ET Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
including T cell engagers developed from our proprietary AnTenGager® platform; ATG-125, a B7-H3 x PD-L1 bispecific antibody-drug conjugate (ADC) designed to combine ADC and immuno-oncology mechanisms; and ATG-207, a globally first-in-class αCD3-TGF-β bifunctional fusion protein for T cell-driven autoimmune
More news about: Antengene Corporation Limited
May 19, 2026, 18:00 ET Ultra Maritime Secures New Contract to Strengthen Royal Australian Navy's Undersea Defence Capabilities
/PRNewswire/ -- Ultra Maritime Australia has been awarded a contract by the Australian Department of Defence to supply Acoustic Device Countermeasure (ADC) units in support of the Royal Australian Navy. This latest agreement reinforces a trusted partnership spanning more than a decade, during which Ultra
More news about: Ultra Maritime
May 18, 2026, 21:35 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform) and ImBiTDC (TDC Platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of
More news about: Nanjing Leads Biolabs Co., Ltd.
May 18, 2026, 08:33 ET Tanmiah Secures Double Win at Product of the Year 2026 Awards, Reinforcing Leadership in Innovation and Local Excellence
May 18, 2026 /PRNewswire/ -- Tanmiah Food Company ("Tanmiah"), through its subsidiary Agricultural Development Company (ADC), a leading provider of fresh and frozen poultry and value-added products, proudly announces a double victory at the prestigious Product of the Year
More news about: Tanmiah Food Company
May 18, 2026, 08:23 ET Tanmiah Secures Double Win at Product of the Year 2026 Awards, Reinforcing Leadership in Innovation and Local Excellence
May 18, 2026 /PRNewswire/ -- Tanmiah Food Company ("Tanmiah"), through its subsidiary Agricultural Development Company (ADC), a leading provider of fresh and frozen poultry and value-added products, proudly announces a double victory at the prestigious Product of the Year
More news about: Tanmiah Food Company
May 17, 2026, 21:13 ET El Día de la Innovación de ACROBiosystems llega a Zúrich
enzimas. En su ponencia titulada "Enzimas inmovilizadas para la fabricación inteligente de productos biológicos: aplicaciones en la producción de ARNm y ADC", presentaron una tecnología patentada que mejora la estabilidad y la reutilización de las enzimas. Presentaron dos estudios de caso: la inmovilización
More news about: ACROBiosystems Group
May 17, 2026, 21:12 ET ACROBiosystems Innovation Day in Zürich bringt führende Köpfe zur Erkundung neuer Biotech-Grenzen zusammen
Herstellung durch die Immobilisierung von Enzymen. In ihrem Vortrag „Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production" stellten sie eine patentierte Technologie vor, die die Stabilität und Wiederverwendbarkeit von Enzymen erhöht. Sie stellten zwei Fallstudien
More news about: ACROBiosystems Group
May 17, 2026, 21:10 ET Zurich accueille la journée de l'innovation d'ACROBiosystems : les plus grands esprits s'unissent pour explorer les frontières de la biotechnologie
fabrication par immobilisation des enzymes. Dans leur exposé intitulé « Immobilized Enzymes for Smart Biologics Manufacturing: Applications in mRNA and ADC Production » (Les enzymes immobilisés pour une fabrication intelligente des médicaments biologiques : applications dans la production d'ARNm et d'ADC),
More news about: ACROBiosystems Group
May 15, 2026, 17:00 ET TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
and development plan for our VISTA inhibitor, TBS-2025, and initiating a Phase 1b/2 trial of TBS-2025 in mutNPM1 r/r AML; selecting our lead ADC for proof-of-concept studies in AML; and completing enrollment in our Phase 3 study of IFx-2.0 in Merkel Cell Carcinoma (MCC)."First Quarter
More news about: TuHURA Biosciences, Inc.
May 15, 2026, 08:00 ET Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual
More news about: Whitehawk Therapeutics, Inc.
May 15, 2026, 03:43 ET Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.